Business
Assessing risk of brain metastasis in lung cancer
Assessing risk of brain metastasis in lung cancer.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n RNS Number : 7696E\n Angle PLC\n 03 March 2020\n \n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n 3 March 2020\n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n BREAKTHROUGH RESEARCH HIGHLIGHTS POTENTIAL FOR PARSORTIX TO ASSESS RISK OF BRAIN METASTASIS IN LUNG CANCER\n \n \n \n \n \n Potential for early detection of patients at risk of brain metastasis in multiple cancers\n \n \n \n \n \n Ground-breaking research by Hamburg-Eppendorf demonstrates role of ALCAM expression in lung cancer brain metastasis and shows that this can be measured on CTCs harvested by Parsortix\n \n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that University Medical Centre Hamburg-Eppendorf has published results of new work undertaken in non-small cell lung cancer (NSCLC) to investigate the causes of brain metastasis utilising ANGLE's Parsortix® system. This ground-breaking research has demonstrated that ALCAM (activated leukocyte cell adhesion molecule) has a key role in causing brain metastasis.\n \n \n \n \n \n The study has shown that the ALCAM protein expression on circulating tumor cells (CTCs), harvested by Parsortix, matches the protein expression in brain metastatic tissue biopsies. \n \n \n \n \n \n This suggests that a Parsortix liquid biopsy blood test may aid in the assessment of the likelihood of a patient suffering a brain metastasis in the future and that the Parsortix blood test may provide additional medical information that could otherwise only be obtained by a highly invasive tissue biopsy of the patient's brain. \n \n \n \n \n \n ALCAM protein expression is understood to play a role in brain metastasis not only for NSCLC but also for breast and prostate cancers. Brain tissue biopsy procedures are rarely undertaken other than where surgical reduction of the tumor is required treatment, given the associated risks. The ability to investigate aspects of the brain metastasis on a repeat basis during treatment via a simple and cost-effective blood test could fundamentally change the standard of care enabling much more focused therapy decisions in the future.\n \n \n \n \n \n The new findings are particularly notable for ANGLE because CTCs from brain m...